Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab with Lenvatinib and SOX in Gastric/GEJ Cancer
NCT07151209Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07151209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07151209.